Sunitinib for metastatic renal cell cancer patients: observational study highlighting the risk of important drug-drug interactions.
about
Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations.Experience with the Implementation of Clinical Pharmacy Services and Processes in a University Hospital in Belgium.Pharmaceutical care program for onco-hematologic outpatients: safety, efficiency and patient satisfaction.Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 2.
P2860
Sunitinib for metastatic renal cell cancer patients: observational study highlighting the risk of important drug-drug interactions.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Sunitinib for metastatic renal ...... ortant drug-drug interactions.
@en
Sunitinib for metastatic renal ...... ortant drug-drug interactions.
@nl
type
label
Sunitinib for metastatic renal ...... ortant drug-drug interactions.
@en
Sunitinib for metastatic renal ...... ortant drug-drug interactions.
@nl
prefLabel
Sunitinib for metastatic renal ...... ortant drug-drug interactions.
@en
Sunitinib for metastatic renal ...... ortant drug-drug interactions.
@nl
P2093
P2860
P356
P1476
Sunitinib for metastatic renal ...... portant drug-drug interactions
@en
P2093
P2860
P304
P356
10.1111/JCPT.12134
P50
P577
2014-01-13T00:00:00Z